GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

Posted by Brenda Bartman on Aug 29th, 2026

GeoVax Labs Inc. (NASDAQ:GOVX – Get Free Report) was the target of a large growth in short interest in August. As of August 14th, there was short interest totaling 182,364 shares, a growth of 218.4% from the July 30th total of 57,276 shares. Based on an average daily trading volume, of 200,659 shares, the days-to-cover ratio is presently 0.9 days. Approximately 5.3% of the shares of the company are short sold.

Institutional Investors Weigh In On GeoVax Labs

A number of large investors have recently bought and sold shares of GOVX. Jane Street Group LLC bought a new position in GeoVax Labs during the first quarter valued at about $27,000. Armistice Capital LLC acquired a new position in shares of GeoVax Labs during the 3rd quarter valued at about $253,000. Renaissance Technologies LLC acquired a new position in shares of GeoVax Labs during the 4th quarter valued at about $104,000. HRT Financial LP bought a new position in shares of GeoVax Labs in the 4th quarter valued at approximately $31,000. Finally, Rice Hall James & Associates LLC bought a new stake in GeoVax Labs during the second quarter worth approximately $1,888,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX traded up $0.00 during trading hours on Friday, hitting $0.72. The stock had a trading volume of 719,030 shares, compared to its average volume of 1,172,538. The firm’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.38. GeoVax Labs has a 52 week low of $0.59 and a 52 week high of $19.20. The company has a market capitalization of $2.50 million, a P/E ratio of -0.06 and a beta of 3.73.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last issued its quarterly earnings data on Monday, July 27th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($2.16) by $1.19. As a group, analysts expect that GeoVax Labs will post -4.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GOVX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $150.00.

View Our Latest Analysis on GOVX

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.